financetom
Business
financetom
/
Business
/
Financial Institutions Inc Q3 profit rises on record interest income
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Financial Institutions Inc Q3 profit rises on record interest income
Oct 23, 2025 1:40 PM

Overview

* Financial Institutions Q3 net income rises to $20.5 mln, up from $13.5 mln year ago

* Net interest income hits record $51.8 mln, reflecting strong loan growth

* Company announces share repurchase program for up to 1,006,379 shares

Outlook

* Company plans to complete BaaS wind-down by early 2026

* Company emphasizes focus on profitable, organic growth for 2025 and 2026

* Company authorized a new share repurchase program for up to 1,006,379 shares

Result Drivers

* NET INTEREST INCOME - Record $51.8 mln net interest income driven by higher yields on loans and securities

* NONINTEREST INCOME - Increased investment advisory and swap fees boost noninterest income

* LOAN GROWTH - Solid commercial loan growth drives total loans to $4.59 bln

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 EPS $0.99

Q3 Net $20.10

Income mln

Q3 Net $51.80

Interest mln

Income

Q3 Net 3.65%

Interest

Margin

(%)

Analyst Coverage

* The one available analyst rating on the shares is "buy"

* The average consensus recommendation for the banks peer group is "buy"

* Wall Street's median 12-month price target for Financial Institutions Inc ( FISI ) is $34.00, about 21.8% above its October 21 closing price of $26.60

* The stock recently traded at 7 times the next 12-month earnings vs. a P/E of 7 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Market Chatter: Carlyle Reportedly Rekindles Plans for Nouryon IPO
Market Chatter: Carlyle Reportedly Rekindles Plans for Nouryon IPO
Sep 16, 2024
02:44 PM EDT, 09/16/2024 (MT Newswires) -- Carlyle Group ( CG ) is once again considering plans to take Nouryon public and has hired investment banks, including Barclays ( JJCTF ) and Goldman Sachs ( GS ) , for help with the IPO, Bloomberg reported Monday citing people familiar with the matter. The company is looking to take the business...
Cullinan Therapeutics Submits Investigational New Drug Application to Treat Systemic Lupus Erythematosus
Cullinan Therapeutics Submits Investigational New Drug Application to Treat Systemic Lupus Erythematosus
Sep 16, 2024
10:25 AM EDT, 09/16/2024 (MT Newswires) -- Cullinan Therapeutics ( CGEM ) said Monday it filed an investigational new drug application to the US Food and Drug Administration to evaluate its CLN-978 to treat systemic lupus erythematosus, a chronic autoimmune disorder. CLN-978 is a half-life extended CD19xCD3 bispecific T cell engager construct, the company said. Price: 18.02, Change: +0.07, Percent...
Accenture Gets $190 Million US Department of State Contract
Accenture Gets $190 Million US Department of State Contract
Sep 16, 2024
10:26 AM EDT, 09/16/2024 (MT Newswires) -- Accenture ( ACN ) unit Accenture Federal Services said Monday it has won a $190 million contract from the US Department of State. Under the contract, Accenture Federal Services will provide data and systems engineering backing for the US President's Emergency Plan for AIDS Relief, the company said. The contract has a base...
BRIEF-U.S. SEC Says Ordered That F-1 IPO Filing Filed By Jiufuyuan Biotechnology Co Ltd Be Declared Abandoned On Sept 16
BRIEF-U.S. SEC Says Ordered That F-1 IPO Filing Filed By Jiufuyuan Biotechnology Co Ltd Be Declared Abandoned On Sept 16
Sep 16, 2024
Sept 16 (Reuters) - * U.S. SEC SAYS ORDERED THAT F-1 IPO FILING FILED BY JIUFUYUAN BIOTECHNOLOGY CO LTD BE DECLARED ABANDONED ON SEPT 16- SEC FILING * U.S. SEC SAYS JIUFUYUAN BIOTECHNOLOGY CO LTD WHICH HAD FILED FOR US IPO IN NOV 2023 FAILED TO RESPOND TO SEC'S NOTICE UNDER RULE 479 Source text - https://bityl.co/S30X Further company coverage:...
Copyright 2023-2026 - www.financetom.com All Rights Reserved